breast cancer and hypercalcemia

Release time ：Dec-19,2024

Breast cancer and hypercalcemia are interconnected conditions. Individuals with breast cancer are at risk of developing hypercalcemia due to the potential for tumor cells to secrete parathyroid hormone-related protein (PTHrP), which mimics the body's parathyroid hormone and facilitates the release of calcium from the bones into the bloodstream, resulting in elevated blood calcium levels. Moreover, breast cancer cells can invade the skeletal system, leading to bone destruction and further increasing serum calcium concentrations.

Hypercalcemia can manifest with symptoms such as fatigue, nausea, vomiting, increased urination, and constipation, with severe cases potentially causing damage to the heart and kidneys. Regular monitoring of serum calcium levels is crucial for breast cancer patients. Upon detection of hypercalcemia, immediate medical consultation and treatment under a physician's guidance are imperative. Treatment options for hypercalcemia include fluid supplementation to enhance urine output, administration of calcitonin or bisphosphonates to inhibit bone resorption, and targeted therapy for the primary tumor.

For breast cancer patients, maintaining a healthy lifestyle is vital for disease management and the prevention of complications. This encompasses a balanced diet, regular physical activity, and maintaining a positive mental attitude. Patients should also closely monitor their health and seek medical attention at the first sign of discomfort. Throughout treatment, adherence to prescribed medication regimens is essential, and patients should not alter dosages or discontinue medication without medical supervision.